Discover recent advancements in near-infrared fluorescence imaging that have revolutionised lymph node tracing in cancers such as breast and penile cancers.

Two enzyme inhibitors join forces in reducing bladder cancer cell proliferation. n 1996, molecular biologist Kun Ping Lu, a ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in ...

ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...

for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without ...

ImmunityBio achieved a 55% disease-free rate at 12 months for BCG-unresponsive NMIBC and plans an sBLA submission in 2025. NSCLC Phase 2b trial (N=86) showed a median overall survival of 14.1 ...

The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors.

for patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) in the papillary indication. 1 Anktiva was previously approved in the US in April 2024 for use in combination with BCG in ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...